305 related articles for article (PubMed ID: 11920636)
1. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.
Reiher FK; Volpert OV; Jimenez B; Crawford SE; Dinney CP; Henkin J; Haviv F; Bouck NP; Campbell SC
Int J Cancer; 2002 Apr; 98(5):682-9. PubMed ID: 11920636
[TBL] [Abstract][Full Text] [Related]
2. CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo.
Koch M; Hussein F; Woeste A; Gründker C; Frontzek K; Emons G; Hawighorst T
Breast Cancer Res Treat; 2011 Jul; 128(2):337-46. PubMed ID: 20714802
[TBL] [Abstract][Full Text] [Related]
3. Selective activity against proliferating tumor endothelial cells by CVX-22, a thrombospondin-1 mimetic CovX-Body.
Coronella J; Li L; Johnson K; Pirie-Shepherd S; Roxas G; Levin N
Anticancer Res; 2009 Jun; 29(6):2243-52. PubMed ID: 19528489
[TBL] [Abstract][Full Text] [Related]
4. c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1.
Jiménez B; Volpert OV; Reiher F; Chang L; Muñoz A; Karin M; Bouck N
Oncogene; 2001 Jun; 20(26):3443-8. PubMed ID: 11423995
[TBL] [Abstract][Full Text] [Related]
5. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms.
Miao WM; Seng WL; Duquette M; Lawler P; Laus C; Lawler J
Cancer Res; 2001 Nov; 61(21):7830-9. PubMed ID: 11691800
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts.
Rofstad EK; Henriksen K; Galappathi K; Mathiesen B
Cancer Res; 2003 Jul; 63(14):4055-61. PubMed ID: 12874006
[TBL] [Abstract][Full Text] [Related]
7. Identification of TAX2 peptide as a new unpredicted anti-cancer agent.
Jeanne A; Sick E; Devy J; Floquet N; Belloy N; Theret L; Boulagnon-Rombi C; Diebold MD; Dauchez M; Martiny L; Schneider C; Dedieu S
Oncotarget; 2015 Jul; 6(20):17981-8000. PubMed ID: 26046793
[TBL] [Abstract][Full Text] [Related]
8. Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat.
Dawson DW; Volpert OV; Pearce SF; Schneider AJ; Silverstein RL; Henkin J; Bouck NP
Mol Pharmacol; 1999 Feb; 55(2):332-8. PubMed ID: 9927626
[TBL] [Abstract][Full Text] [Related]
9. Thrombospondin-1 treatment prevents growth of dormant lung micrometastases after surgical resection and curative radiation therapy of the primary tumor in human melanoma xenografts.
Rofstad EK; Galappathi K; Mathiesen B
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):493-9. PubMed ID: 14751520
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats.
Iruela-Arispe ML; Lombardo M; Krutzsch HC; Lawler J; Roberts DD
Circulation; 1999 Sep; 100(13):1423-31. PubMed ID: 10500044
[TBL] [Abstract][Full Text] [Related]
11. An N-terminal 80 kDa recombinant fragment of human thrombospondin-2 inhibits vascular endothelial growth factor induced endothelial cell migration in vitro and tumor growth and angiogenesis in vivo.
Noh YH; Matsuda K; Hong YK; Kunstfeld R; Riccardi L; Koch M; Oura H; Dadras SS; Streit M; Detmar M
J Invest Dermatol; 2003 Dec; 121(6):1536-43. PubMed ID: 14675207
[TBL] [Abstract][Full Text] [Related]
12. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
Allegrini G; Goulette FA; Darnowski JW; Calabresi P
Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
[TBL] [Abstract][Full Text] [Related]
13. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1.
Jiménez B; Volpert OV; Crawford SE; Febbraio M; Silverstein RL; Bouck N
Nat Med; 2000 Jan; 6(1):41-8. PubMed ID: 10613822
[TBL] [Abstract][Full Text] [Related]
14. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells.
Dawson DW; Pearce SF; Zhong R; Silverstein RL; Frazier WA; Bouck NP
J Cell Biol; 1997 Aug; 138(3):707-17. PubMed ID: 9245797
[TBL] [Abstract][Full Text] [Related]
15. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis.
Izawa JI; Sweeney P; Perrotte P; Kedar D; Dong Z; Slaton JW; Karashima T; Inoue K; Benedict WF; Dinney CP
Clin Cancer Res; 2002 Apr; 8(4):1258-70. PubMed ID: 11948141
[TBL] [Abstract][Full Text] [Related]
17. Cyclic thrombospondin-1 mimetics: grafting of a thrombospondin sequence into circular disulfide-rich frameworks to inhibit endothelial cell migration.
Chan LY; Craik DJ; Daly NL
Biosci Rep; 2015 Oct; 35(6):. PubMed ID: 26464514
[TBL] [Abstract][Full Text] [Related]
18. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities.
Haviv F; Bradley MF; Kalvin DM; Schneider AJ; Davidson DJ; Majest SM; McKay LM; Haskell CJ; Bell RL; Nguyen B; Marsh KC; Surber BW; Uchic JT; Ferrero J; Wang YC; Leal J; Record RD; Hodde J; Badylak SF; Lesniewski RR; Henkin J
J Med Chem; 2005 Apr; 48(8):2838-46. PubMed ID: 15828822
[TBL] [Abstract][Full Text] [Related]
19. Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide.
Jeanne A; Boulagnon-Rombi C; Devy J; Théret L; Fichel C; Bouland N; Diebold MD; Martiny L; Schneider C; Dedieu S
Clin Exp Metastasis; 2016 Oct; 33(7):637-49. PubMed ID: 27349907
[TBL] [Abstract][Full Text] [Related]
20. The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.
Ruggeri BA; Robinson C; Angeles T; Wilkinson J; Clapper ML
Clin Cancer Res; 2002 Jan; 8(1):267-74. PubMed ID: 11801568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
